Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. ASCO GU 2021: Recommendations From Dr. Jun Gong
  2. Survival Nomograms for Patients With Bone Metastatic RCC
  3. Nomogram Predicting Survival to Assist Decision-Making of Metastasectomy in Patients With Metastatic RCC
  4. Axitinib Plus Pembrolizumab in Advanced RCC
  5. Low Intratumor Heterogeneity Correlates With Increased Response to PD-1 Blockade in RCC
  6. Age-Based Outcomes in Patients With mRCC Treated With First-Line Targeted Therapy or Checkpoint Immunotherapy
  7. Association of Surgical Delay and Overall Survival in Patients With T2 Renal Masses
  8. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients With mRCC
  9. 18F-PSMA-1007 PET/CT for Response Assessment in Patients With mRCC Undergoing Systemic Therapy
  10. Obesity Diminishes Response to PD-1–Based Immunotherapies in Renal Cancer

Elsewhere

Recently Updated